Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

BACKGROUND: Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refractory cases. CPI‐related gastroenterocolitis (GEC) affects 20%‐5...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Michael S., Zheng, Hui, Zubiri, Leyre, Molina, Gabriel E., Chen, Steven T., Mooradian, Meghan J., Allen, Ian M., Reynolds, Kerry L., Dougan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718531/
https://www.ncbi.nlm.nih.gov/pubmed/31286682
http://dx.doi.org/10.1002/cam4.2397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718531/
https://www.ncbi.nlm.nih.gov/pubmed/31286682
http://dx.doi.org/10.1002/cam4.2397

Ejemplares similares